CoChat

Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids

Open access

Published version of a preprint

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index; none of the 58 sources its claims cite is checked for support yet.

Abstract

Retinal ganglion cells (RGCs) serve as the connection between the eye and the brain, with this connection disrupted in glaucoma. Numerous cellular mechanisms have been associated with glaucomatous neurodegeneration, and useful cellular models of glaucoma allow for the precise analysis of degenerative phenotypes. Human pluripotent stem cells (hPSCs) serve as powerful tools for studying human disease, particularly cellular mechanisms underlying neurodegeneration. Thus, efforts focused upon hPSCs with an E50K mutation in the Optineurin (OPTN) gene, a leading cause of inherited forms of glaucoma. CRISPR/Cas9 gene editing introduced the OPTN(E50K) mutation into existing lines of hPSCs, as well as generating isogenic controls from patient-derived lines. RGCs differentiated from OPTN(E50K) hPSCs exhibited numerous neurodegenerative deficits, including neurite retraction, autophagy dysfunction, apoptosis, and increased excitability. These results demonstrate the utility of OPTN(E50K) RGCs as an in vitro model of neurodegeneration, with the opportunity to develop novel therapeutic approaches for glaucoma.

Overview

CoChat Summary

TL;DR

CRISPR/Cas9 was used to introduce or correct the glaucoma-associated OPTN(E50K) mutation in human pluripotent stem cells, and RGCs derived from three-dimensional retinal organoids were characterized over maturation. OPTN(E50K) RGCs showed neurodegenerative phenotypes including neurite retraction, autophagy dysfunction, apoptosis, and increased excitability.

Key findings

  • Early retinal differentiation was comparable between OPTN(E50K) and isogenic controls: no significant differences in PAX6, CHX10, BRN3B:tdTomato, RBPMS, or SNCG, with similar RGC numbers (n = 5 separate differentiation experiments).
  • By 4 weeks after RGC purification, OPTN(E50K) RGCs had significantly fewer ordered neurites and branch points, shorter neurites, and smaller soma; BRN3B and ISL1 were significantly decreased relative to MAP2/DAPI, while MAP2, CHX10, recoverin, and OTX2 populations were not significantly changed (n = 3–4 separate differentiation experiments).
  • Patch-clamp recordings showed no significant resting membrane potential difference, but OPTN(E50K) RGCs had significantly lower cell capacitance, higher input resistance, lower action potential current threshold, and fired significantly more action potentials (n = 2 differentiations; H7 n = 28 technical replicates, H7(E50K) n = 46 technical replicates).
  • RNA sequencing found 75 downregulated and 117 upregulated genes in OPTN(E50K) RGCs (p < 0.05), with pathways related to autophagy and neurite outgrowth; OPTN(E50K) organoids showed inner-layer LC3 accumulation and increased active caspase-3, both reduced by rapamycin (2 μM, 24 h).

Methods

  • CRISPR/Cas9 homology-directed repair introduced OPTN(E50K) into H7BRN3B:tdTomatoThy1.2 hESCs and corrected the mutation in patient-derived hiPSCs; clones were screened by Hpy188III digestion and Sanger sequencing, with normal karyotypes confirmed.
  • hPSCs were differentiated into three-dimensional retinal organoids; at day 45, RGCs were purified by Thy1.2 MACS, plated on poly-D-ornithine/laminin, and maintained up to 4 weeks in BrainPhys medium.
  • Analyses included immunocytochemistry, ImageJ/NeuronJ neurite and soma quantification, whole-cell patch-clamp electrophysiology, and RNA sequencing with DESeq2 and pathway enrichment (GEO accession GSE145069); statistics used t tests or one-way ANOVA with Tukey’s post hoc test.

Limitations

  • Stated: BRN3B:tdTomato reporter downregulation at advanced OPTN(E50K) RGC stages may mean recorded phenotypes represent an earlier degenerative stage, and future experiments using fluorescent reporters must account for this downregulation.
  • Evident: the paper has no dedicated limitations section; electrophysiology was limited to n = 2 differentiation experiments (H7 and H7(E50K)), and several assays used n = 3–5 differentiation experiments, so broader cell-line and differentiation-batch variability is not fully addressed.
  • Evident: the study examines only the OPTN(E50K) mutation, so findings may not generalize to other glaucoma-associated mutations or patient backgrounds.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.stemcr.2020.05.009

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
Figure 1 CRISPR/Cas9 Gene Editing for the Generation of OPTN(E50K) hPSCs and Corresponding Isogenic Controls (A) Schematic displaying the workflow for the CRISPR/Cas9 gene editing of hPSCs. (B) A subset of GFP-positive cells was observed in hPSCs expressing Nanog and Tra1-81 after electroporation. (C) Flow cytometry indicated the gating of GFP-positive cells 48 h after electroporation. (D and E) CRISPR/Cas9-edited cells were screened for the insertion of the OPTN(E50K) mutation in wild-type hPSCs (D) and correction of the mutation in patient-derived hPSCs (E) by restriction digestion with Hpy188III and Sanger sequencing. The 50th codon of the OPTN gene is highlighted in yellow. The red arrows highlight the insertion or correction of the OPTN(E50K) missense mutation site in Sanger sequencing. Scale bar, 50 μm (B).
Figure 1 CRISPR/Cas9 Gene Editing for the Generation of OPTN(E50K) hPSCs and Corresponding Isogenic Controls (A) Schematic displaying the workflow for the CRISPR/Cas9 gene editing of hPSCs. (B) A subset of GFP-positive cells was observed in hPSCs expressing Nanog and Tra1-81 after electroporation. (C) Flow cytometry indicated the gating of GFP-positive cells 48 h after electroporation. (D and E) CRISPR/Cas9-edited cells were screened for the insertion of the OPTN(E50K) mutation in wild-type hPSCs (D) and correction of the mutation in patient-derived hPSCs (E) by restriction digestion with Hpy188III and Sanger sequencing. The 50th codon of the OPTN gene is highlighted in yellow. The red arrows highlight the insertion or correction of the OPTN(E50K) missense mutation site in Sanger sequencing. Scale bar, 50 μm (B).CC BY-NC-ND · PubMed Central
Figure 2 The OPTN(E50K) Mutation Does Not Affect Early Stages of Retinal Differentiation (A–D) Immunocytochemistry analyzed the expression of PAX6 (A and B) and CHX10 (C and D) at 30 days of differentiation, revealing no significant differences between OPTN(E50K) and isogenic control retinal organoids. (E and F) Similarly, both conditions demonstrated similar expression patterns for BRN3B:tdTomato within inner layers and Recoverin within outer layers of retinal organoids after 60 days of differentiation. (G–M) RGCs dissociated from OPTN(E50K) (H, J, and L) and isogenic control (G, I, and K) retinal organoids demonstrated no significant differences in the expression of BRN3B:tdTomato, RBPMS, and SNCG (M). Error bars represent SEM (n = 5 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN- corrected hiPSCs, and H7 and H7(E50K) hPSCs). Scale bars, 100 μm (A–F) and 50 μm (G–L).
Figure 2 The OPTN(E50K) Mutation Does Not Affect Early Stages of Retinal Differentiation (A–D) Immunocytochemistry analyzed the expression of PAX6 (A and B) and CHX10 (C and D) at 30 days of differentiation, revealing no significant differences between OPTN(E50K) and isogenic control retinal organoids. (E and F) Similarly, both conditions demonstrated similar expression patterns for BRN3B:tdTomato within inner layers and Recoverin within outer layers of retinal organoids after 60 days of differentiation. (G–M) RGCs dissociated from OPTN(E50K) (H, J, and L) and isogenic control (G, I, and K) retinal organoids demonstrated no significant differences in the expression of BRN3B:tdTomato, RBPMS, and SNCG (M). Error bars represent SEM (n = 5 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN- corrected hiPSCs, and H7 and H7(E50K) hPSCs). Scale bars, 100 μm (A–F) and 50 μm (G–L).CC BY-NC-ND · PubMed Central
Figure 3 OPTN(E50K) RGCs Demonstrate Neurite Deficits at Later Stages of Maturation (A–P) Inverted fluorescent images (A–H) and representative neurite tracings (I–P) of isogenic control and OPTN(E50K) RGCs from 1 to 4 weeks after purification from retinal organoids. Similar neurite complexity was initially observed, but significant neurite retraction in OPTN(E50K) RGCs became apparent at 4 weeks. (Q) A significantly lower number of ordered neurites and branch points were observed in OPTN(E50K) RGCs after 4 weeks. (R and S) OPTN(E50K) RGCs also demonstrated significantly shorter neurites (R) and smaller soma sizes (S) by 4 weeks of maturation. Error bars represent SEM (n = 4 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and H7(E50K) hPSCs) (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). Scale bars, 25 μm (A–H) and 100 μm (I–P).
Figure 3 OPTN(E50K) RGCs Demonstrate Neurite Deficits at Later Stages of Maturation (A–P) Inverted fluorescent images (A–H) and representative neurite tracings (I–P) of isogenic control and OPTN(E50K) RGCs from 1 to 4 weeks after purification from retinal organoids. Similar neurite complexity was initially observed, but significant neurite retraction in OPTN(E50K) RGCs became apparent at 4 weeks. (Q) A significantly lower number of ordered neurites and branch points were observed in OPTN(E50K) RGCs after 4 weeks. (R and S) OPTN(E50K) RGCs also demonstrated significantly shorter neurites (R) and smaller soma sizes (S) by 4 weeks of maturation. Error bars represent SEM (n = 4 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and H7(E50K) hPSCs) (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001). Scale bars, 25 μm (A–H) and 100 μm (I–P).CC BY-NC-ND · PubMed Central
Figure 4 OPTN(E50K) RGCs Downregulate RGC-Associated Transcription Factors (A and B) The expression of RGC-associated transcription factors BRN3B:tdTomato (A) and ISL1 (B) was correlated with the RGC-associated cytoskeletal marker MAP2, with this correlation decreased in the OPTN(E50K) cell lines. (C and D) Conversely, minimal correlation was observed between MAP2 and markers of retinal progenitor cells (C, CHX10) and photoreceptors (D, OTX2). (E) A significant decrease was observed in the expression of BRN3B and ISL1 in OPTN(E50K) RGCs relative to the total number of DAPI-positive cells, with no differences observed in MAP2-expressing cells nor CHX10-expressing retinal progenitor cells or Recoverin/OTX2-expressing photoreceptors. (F) A significant decrease in co-expression for BRN3 or ISL1 RGCs was observed, with no changes observed for other cell types. (G) Lastly, as either a percentage of the total cell population or among the MAP2-expressing cells, changes in cell numbers were only observed among RGCs as identified by BRN3 expression. Error bars represent SEM (n = 3 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and H7(E50K) hPSCs) (∗∗p < 0.01, ∗∗∗p < 0.001). Scale bars, 25 μm (A–D).
Figure 4 OPTN(E50K) RGCs Downregulate RGC-Associated Transcription Factors (A and B) The expression of RGC-associated transcription factors BRN3B:tdTomato (A) and ISL1 (B) was correlated with the RGC-associated cytoskeletal marker MAP2, with this correlation decreased in the OPTN(E50K) cell lines. (C and D) Conversely, minimal correlation was observed between MAP2 and markers of retinal progenitor cells (C, CHX10) and photoreceptors (D, OTX2). (E) A significant decrease was observed in the expression of BRN3B and ISL1 in OPTN(E50K) RGCs relative to the total number of DAPI-positive cells, with no differences observed in MAP2-expressing cells nor CHX10-expressing retinal progenitor cells or Recoverin/OTX2-expressing photoreceptors. (F) A significant decrease in co-expression for BRN3 or ISL1 RGCs was observed, with no changes observed for other cell types. (G) Lastly, as either a percentage of the total cell population or among the MAP2-expressing cells, changes in cell numbers were only observed among RGCs as identified by BRN3 expression. Error bars represent SEM (n = 3 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and H7(E50K) hPSCs) (∗∗p < 0.01, ∗∗∗p < 0.001). Scale bars, 25 μm (A–D).CC BY-NC-ND · PubMed Central
Figure 5 OPTN(E50K) RGCs Display Increased Excitability (A and B) OPTN(E50K) RGCs and isogenic controls displayed similar abilities to conduct inward sodium and outward potassium currents (A) as well as the ability to fire spontaneous action potentials (B). (C) No significant differences were identified in the resting membrane potential between OPTN(E50K) RGCs and isogenic controls. (D–F) OPTN(E50K) RGCs demonstrated significantly lower cell capacitance (D), higher input resistance (E), and a lower action potential current threshold (F) compared with isogenic controls. (G and H) Representative traces of evoked action potentials (G) following current injections revealed the firing of significantly more action potentials (H) in OPTN(E50K) RGCs compared with isogenic controls. Error bars represent SEM (n = 2 separate differentiation experiments using H7, n = 28 technical replicates and H7(E50K) hPSCs, n = 46 technical replicates) (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
Figure 5 OPTN(E50K) RGCs Display Increased Excitability (A and B) OPTN(E50K) RGCs and isogenic controls displayed similar abilities to conduct inward sodium and outward potassium currents (A) as well as the ability to fire spontaneous action potentials (B). (C) No significant differences were identified in the resting membrane potential between OPTN(E50K) RGCs and isogenic controls. (D–F) OPTN(E50K) RGCs demonstrated significantly lower cell capacitance (D), higher input resistance (E), and a lower action potential current threshold (F) compared with isogenic controls. (G and H) Representative traces of evoked action potentials (G) following current injections revealed the firing of significantly more action potentials (H) in OPTN(E50K) RGCs compared with isogenic controls. Error bars represent SEM (n = 2 separate differentiation experiments using H7, n = 28 technical replicates and H7(E50K) hPSCs, n = 46 technical replicates) (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).CC BY-NC-ND · PubMed Central
Figure 6 RNA Sequencing Revealed Differential Gene Expression and Pathway Analysis in OPTN(E50K) RGCs (A) A schematic demonstrates the workflow of RNA sequencing from OPTN(E50K) and isogenic control retinal organoids (n = 4 for isogenic control and n = 4 for OPTN(E50K)). (B) Differential gene expression analysis demonstrated 75 downregulated genes and 117 upregulated genes in OPTN(E50K) RGCs when compared with isogenic control RGCs (p < 0.05). (C) Pathway analysis revealed a variety of upregulated and downregulated pathways associated with glaucomatous neurodegeneration (p < 0.1). n = 5 separate differentiation experiments using H7 and H7(E50K) hPSCs.
Figure 6 RNA Sequencing Revealed Differential Gene Expression and Pathway Analysis in OPTN(E50K) RGCs (A) A schematic demonstrates the workflow of RNA sequencing from OPTN(E50K) and isogenic control retinal organoids (n = 4 for isogenic control and n = 4 for OPTN(E50K)). (B) Differential gene expression analysis demonstrated 75 downregulated genes and 117 upregulated genes in OPTN(E50K) RGCs when compared with isogenic control RGCs (p < 0.05). (C) Pathway analysis revealed a variety of upregulated and downregulated pathways associated with glaucomatous neurodegeneration (p < 0.1). n = 5 separate differentiation experiments using H7 and H7(E50K) hPSCs.CC BY-NC-ND · PubMed Central
Figure 7 OPTN(E50K) Retinal Organoids Demonstrate Autophagy Dysfunction through LC3 Accumulation (A–I) Retinal organoids from isogenic control, OPTN(E50K), and OPTN(E50K) plus rapamycin conditions displayed proper organization with BRN3B:tdTomato expression confined within inner layers. Compared with isogenic controls (A–C), LC3 accumulations were found specifically within the inner layers of OPTN(E50K) organoids (D–F), with accumulation rescued by rapamycin treatment (G–I). Arrowheads in (E) indicate LC3 accumulations. (J–L) Significantly more LC3 puncta (J) were observed in OPTN(E50K) organoids compared with isogenic controls or rapamycin-treated organoids, with accumulations larger in both puncta size (K) and total area (L). (M–S) OPTN(E50K) retinal organoids (O and P) also displayed significantly higher levels of active caspase-3 within inner layers compared with outer layers as well as corresponding isogenic controls (M and N), with increased active caspase-3 rescued by rapamycin (Q and R). Error bars represent SEM (n = 3 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and H7(E50K) hPSCs) (∗p < 0.05, ∗∗∗∗p < 0.0001). Images in (C), (F), and (I) are higher magnification representations of samples analyzed in (B), (E), and (H). Scale bars, 50 μm.
Figure 7 OPTN(E50K) Retinal Organoids Demonstrate Autophagy Dysfunction through LC3 Accumulation (A–I) Retinal organoids from isogenic control, OPTN(E50K), and OPTN(E50K) plus rapamycin conditions displayed proper organization with BRN3B:tdTomato expression confined within inner layers. Compared with isogenic controls (A–C), LC3 accumulations were found specifically within the inner layers of OPTN(E50K) organoids (D–F), with accumulation rescued by rapamycin treatment (G–I). Arrowheads in (E) indicate LC3 accumulations. (J–L) Significantly more LC3 puncta (J) were observed in OPTN(E50K) organoids compared with isogenic controls or rapamycin-treated organoids, with accumulations larger in both puncta size (K) and total area (L). (M–S) OPTN(E50K) retinal organoids (O and P) also displayed significantly higher levels of active caspase-3 within inner layers compared with outer layers as well as corresponding isogenic controls (M and N), with increased active caspase-3 rescued by rapamycin (Q and R). Error bars represent SEM (n = 3 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and H7(E50K) hPSCs) (∗p < 0.05, ∗∗∗∗p < 0.0001). Images in (C), (F), and (I) are higher magnification representations of samples analyzed in (B), (E), and (H). Scale bars, 50 μm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 23 Not checked · 64 Own results and interpretations

44 more claims

Create a free account to see all 87 claims and to verify the 57 references still open.

See all claims — free account
  • It may state two separate claims as one. 20
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 22

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

9 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 67 references

Cited by

Items 101–108 of 108

Metadata

Authors
VanderWall, K. B., Huang, K.-C., Pan, Y., Lavekar, S. S., Fligor, C. M., Allsop, A. R., Lentsch, K. A., Dang, P., Zhang, C., Tseng, H. C., Cummins, T. R., & Meyer, J. S.
Affiliations
  • Indiana University – Purdue University Indianapolis (US)
  • Indiana University School of Medicine (US)
  • Duke Medical Center (US)
  • Indiana University Indianapolis (US)
Corresponding author
Meyer, Jason S.
Venue
Stem Cell Reports
Publisher
Elsevier BV
Published
2020-07
Volume
15
Issue
1
Pages
52-66
ISSN
2213-6711 (ISSN-L)
OpenAlex
W3034201929
Cited by
108
References
67
Citations by year
2026: 18 · 2025: 17 · 2024: 23 · 2023: 17 · 2022: 10 · 2021: 18 · 2020: 5
FWCI
9.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Reports (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
  • PMC
Funders
  • National Institutes of Health
  • National Eye Institute (R01 EY024984, R21 EY031120)
  • National Center for Advancing Translational Sciences
  • Indiana State Department of Health
  • Brain Injury Research Center (26343)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
glaucoma, retinal ganglion cells, optineurin, neurodegeneration, retinal organoids, human pluripotent stem cells, CRISPR/Cas9 genome editing, isogenic controls, neurite retraction, autophagy dysfunction, apoptosis, neuronal excitability, in vitro disease model
MeSH terms
Gene Editing, Animals, Autophagy, Cell Differentiation, Disease Models, Animal, Glaucoma, Humans, Microtubule-Associated Proteins, Mutation, Nerve Degeneration, Organoids, Phenotype, Retinal Ganglion Cells, Down-Regulation, Apoptosis, Sequence Analysis, RNA, Cell Cycle Proteins, Membrane Transport Proteins, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.